Erben Pia B, Brunner Kathrin, Hecht Markus, Haderlein Marlen, Büttner-Herold Maike, Agaimy Abbas, Fietkau Rainer, Hartmann Arndt, Distel Luitpold V
Institute of Pathology, The University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg Erlangen, Germany.
Department of Radiation Oncology, The University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg Erlangen, Germany.
Int J Clin Exp Pathol. 2015 Dec 1;8(12):15814-24. eCollection 2015.
KPNA2 has effects on carcinogenesis, cell differentiation and transcriptional regulation. KPNA2 has been linked to DNA damage repair by its role to import the DNA double strand break repair complex MRN into the nucleus. The aim of our study was to evaluate the prognostic value of KPNA2 expression in both cytoplasmic and nuclear location in patients with HNSCC treated with radio(chemo)therapy.
225 patients with HNSCC treated with neoadjuvant, definitive or adjuvant radio(chemo)therapy were included. Immunohistochemical staining was performed on tissue micro arrays to evaluate nuclear and cytoplasmic KPNA2 expression.
The median fraction of tumor cells with nuclear KPNA2 expression was 15%. 47% of tumor samples showed positive cytoplasmic staining. Patients with low nuclear as well as negative cytoplasmic expression tended to have an unfavorable prognosis. There was no correlation between nuclear and cytoplasmic KPNA2 expression. Low nuclear combined with negative cytoplasmic KPNA2 had a clearly unfavorable prognostic effect in local failure-free survival (P=0.014), metastasis-free survival (P=0.001) and no evidence of disease (P=0.008). A combination of low nuclear/negative cytoplasmic with high nuclear/high cytoplasmic KPNA2 expression was prognostically unfavorable with regard to tumor specific survival (P=0.021) and to a lower extent to overall survival (P=0.18). In multivariate analysis low nuclear/negative cytoplasmic versus any high KPNA2 (P=0.008) and T-category (P=0.002) proved as independent prognostic variables.
The combination of nuclear and cytoplasmic KPNA2 expression is a potential excellent prognostic parameter in HNSCC treated with radio(chemo)therapy.
核转运蛋白α2(KPNA2)对肿瘤发生、细胞分化及转录调控有影响。KPNA2通过将DNA双链断裂修复复合物MRN导入细胞核的作用与DNA损伤修复相关。本研究旨在评估接受放(化)疗的头颈部鳞状细胞癌(HNSCC)患者中KPNA2在细胞质和细胞核定位表达的预后价值。
纳入225例接受新辅助、根治性或辅助放(化)疗的HNSCC患者。在组织微阵列上进行免疫组化染色,以评估细胞核和细胞质中KPNA2的表达。
细胞核中KPNA2表达的肿瘤细胞中位比例为15%。47%的肿瘤样本显示细胞质染色阳性。细胞核表达低以及细胞质表达阴性的患者往往预后不良。细胞核和细胞质中KPNA2的表达之间无相关性。细胞核表达低合并细胞质KPNA2阴性在无局部复发生存率(P=0.014)、无转移生存率(P=0.001)和无疾病证据(P=0.008)方面具有明显不良的预后影响。细胞核/细胞质低表达与细胞核/细胞质高表达的组合在肿瘤特异性生存率(P=0.021)方面预后不良,在总体生存率方面(P=0.18)影响较小。多因素分析显示,细胞核/细胞质低表达与任何高KPNA2表达(P=0.008)和T分期(P=0.002)是独立的预后变量。
在接受放(化)疗的HNSCC中,细胞核和细胞质KPNA2表达的组合是一个潜在的优秀预后参数。